Boathouse Capital and BioPharm Communications Completes Acquisition of Carson Analytics
October 16, 2014
BioPharm Communications, a portfolio company of Southfield Capital and minority shareholder Boathouse Capital, is pleased to announce the acquisition of Carson Analytics. Carson Analytics is a leading provider of integrated commercial analytics solutions for the pharmaceutical and biotechnology industries. Carson Analytics’ senior management will continue in their current operating role and maintain a minority ownership in the company.
Headquartered in Long Valley, NJ, Carson Analytics (www.carsonanalytics.com) provides advanced analytics solutions including forecasting, promotion response analysis and optimization of promotion mix. These capabilities will allow BioPharm to further increase the value of its programs through evidence-based insights.
“We are thrilled about the integration of Carson’s capabilities with ours. This acquisition will allow us to provide our clients with better visibility and transparency into the effectiveness of their promotional spend. These analytics-driven decision support capabilities will enable our clients to maximize the ROI on their campaigns,” says Jeff Persinger, President and CEO of BioPharm. According to Daniel Egeland, Chief Sales and Marketing Officer at BioPharm, “The acquisition of Carson will allow us to deliver new solutions to our clients, and they will benefit greatly from our intense focus on measuring campaign effectiveness and monitoring responsiveness of target healthcare providers. The result of this evidence-based approach will allow clients to deploy the right tactics against the right targets.”
“Carson Analytics is excited about the opportunity to partner with BioPharm Communications,” reports Lars Nordmann, founder of Carson Analytics. “This is a synergistic combination that will allow us to provide our analytics solutions to a broader range of clients and will also add incremental value to BioPharm’s existing service offerings.”